Cuộc họp công bố kết quả kinh doanh Quý 2/2026 của CorMedix (CRMD): Doanh thu đạt 101,9 triệu USD, nâng dự báo EBITDA
Doanh thu quý II/2026 của CorMedix đạt 101,9 triệu USD, EBITDA điều chỉnh đạt 58,7 triệu USD, và ban lãnh đạo đã nâng dự báo EBITDA cả năm lên mức 125 triệu - 140 triệu USD.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.